London Health Sciences Centre-University Campus
339 Windermere Road
London, ON, Canada N6A 5A5
Tel: 519.685.8500 ext. 34945
The development of outcome measures for evaluation of new treatments for IBD and designing and conducting clinical trials.
Dr. Reena Khanna is an Associate Professor of Medicine at the University of Western Ontario, and a Clinician Researcher in the Program for Experimental Medicine. She completed her MD and Internal Medicine residency at the University of Western Ontario, Gastroenterology fellowship at McMaster University. Dr. Khanna completed an advanced fellowship in inflammatory bowel disease (IBD) at the Cleveland Clinic, followed by a research fellowship in international IBD clinical trials at the University of Western Ontario. She completed an MSc in clinical epidemiology at McMaster University. Her clinical and research interest are clinical trial design, new therapeutics, outcome measures. Dr. Khanna holds international grants and most recently was awarded the Crohn’s Colitis Canada’s rising star award for her research contributions.
Khanna R, Zou G, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, McDonald JW, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D’Haens G. Responsiveness of Endoscopic Indices of Disease Activity for Crohn’s Disease. Am J Gastroenterol, 2017 Jan 10, Principal Author, DOI: 10.1038/ajg.2016.580.
Khanna R, Jairath V, Vande Casteele N, Mosli MH, Zou G, Parker CE, Levesque BG, Sandborn WJ, D’Haens G, Feagan BG. Efficient Early Drug Development for Ulcerative Colitis. Gastroenterology, 2016 Mar 23, Co-Principal Author, DOI: 10.1053/j.gastro.2016.03.013.
Khanna R, Nelson SA, Feagan BG, D’Haens G, Sandborn WJ, Zou GY, MacDonald JK, Parker CE, Jairath V, Levesque BG. Endoscopic scoring indices for evaluation of disease activity in Crohn’s disease. Cochrane Database Syst Rev, 2016 Aug 8 (8): CD010642, Principal Author, DOI: 10.1002/14651858.CD010642.pub2.
Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, Panaccione R, Bitton A, Paré P, Vermeire S, D’Haens G, MacIntosh D, Sandborn WJ, Donner A, Vandervoort MK, Morris JC, Feagan BG, REACT Study Investigators. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet, 2015 Sep 2, Principal Author, DOI: 10.1016/S0140-6736(15)00068-9.
Khanna R, Zou G, D’Haens G, Rutgeerts P, McDonald JW, Daperno M, Feagan BG, Sandborn WJ, Dubcenco E, Stitt L, Vandervoort MK, Donner A, Luo A, Levesque BG. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn’s disease. Gut, 2015 May 2, Principal Author, DOI: 10.1136/gutjnl-2014-308973.
Khanna R, Zou G, D’Haens G, Feagan BG, Sandborn WJ, Vandervoort MK, Rolleri RL, Bortey E, Paterson C, Forbes WP, Levesque BG. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn’s disease activity. Aliment Pharmacol Ther, 2015 Jan 1; 41 (1): 77-86, Principal Author, DOI: 10.1111/apt.13001.
Khanna R, Sattin BD, Afif W, Benchimol EI, Bernard EJ, Bitton A, Bressler B, Fedorak RN, Ghosh S, Greenberg GR, Marshall JK, Panaccione R, Seidman EG, Silverberg MS, Steinhart AH, Sy R, Van Assche G, Walters TD, Sandborn WJ, Feagan BG. Review article: a clinician’s guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther, 2013 Sep 1; 38 (5): 447-59, Principal Author, DOI: 10.1111/apt.12407.